Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration by Hasegawa, Tomoko et al.
TitleNeuoroprotective efficacies by KUS121, a VCP modulator, onanimal models of retinal degeneration
Author(s)
Hasegawa, Tomoko; Muraoka, Yuki; Ikeda, Hanako Ohashi;
Tsuruyama, Tatsuaki; Kondo, Mineo; Terasaki, Hiroko;
Kakizuka, Akira; Yoshimura, Nagahisa




This work is licensed under a Creative Commons Attribution
4.0 International License. The images or other third party
material in this article are included in the article's Creative
Commons license, unless indicated otherwise in the credit line;
if the material is not included under the Creative Commons
license, users will need to obtain permission from the license





1Scientific RepoRts | 6:31184 | DOI: 10.1038/srep31184
www.nature.com/scientificreports
Neuoroprotective efficacies 
by KUS121, a VCP modulator, 
on animal models of retinal 
degeneration
Tomoko Hasegawa1,*, Yuki Muraoka1,*, Hanako Ohashi Ikeda1,2, Tatsuaki Tsuruyama3, 
Mineo Kondo4, Hiroko Terasaki5, Akira Kakizuka6 & Nagahisa Yoshimura1
Retinitis pigmentosa (RP) is one of the leading causes of adult blindness and has no established therapy. 
We have shown that valosin-containing protein (VCP) modulators, Kyoto University Substances (KUSs), 
ameliorated abnormally low ATP levels by inhibiting the ATPase of VCP, thereby protected several types 
of cells, including retinal neurons, from cell death-inducing insults. In this study, we found that KUS121, 
one of the VCP modulators, effectively protects photoreceptors both morphologically and functionally, 
in two animal models of retinal degeneration, rd12 mice and RP rabbits with a rhodopsin (Pro347Leu) 
mutation. In rd12 mice, KUS121 suppressed the loss of photoreceptors, not only rods but also cones, 
as well as the visual function deterioration. Significant protective effects existed even when the 
medication was started in later stages of the disease. In RP rabbits, KUS121 suppressed thinning of the 
outer nuclear layer and maintained visual function. In the retinas treated with KUS121, suppression of 
endoplasmic reticulum stress, activation of mammalian target of rapamycin and suppression of disease-
associated apoptosis were evident. The ability of KUS121 to protect photoreceptors, especially cones, 
even in later stages of the disease may contribute to the preservation of central vision in RP patients, 
which is important for quality of vision.
Retinitis pigmentosa (RP) is one of the leading causes of adult blindness, with approximately 1.5 million affected 
people around the world, and an incidence of approximately 1 in 4,000 people. RP results from many different 
genetic etiologies, and dominant, recessive, and sex-linked modes of inheritance are known. More than 45 genes 
have been reported to cause the disease, which includes genes associated with the phototransduction cascade, 
vitamin A metabolism, signaling, and so on1,2.
Recently, clinical trials of gene therapy are being conducted with RP patients with RPE65 (retinal pigment 
epithelium-specific protein 65 kD) mutations3–5. RPE65 is involved in the conversion of all-trans retinol to 11-cis 
retinal during photoreceptor phototransduction and visual pigment regeneration. Although gene therapy seems 
to be a potentially effective therapeutic strategy, the diagnosis of causative genes is prerequisite. It is impor-
tant to note that current capabilities of identification of causative genes remain as low as 36.3–51%, even using 
next-generation sequencing6,7. In addition, the percentage of RP patients with an RPE65 mutation is small (only 
1–2% of RP patients)2,7. Regenerative medicine is another therapeutic strategy8 and may benefit patients with 
advanced-stage degeneration. In the meantime, however, therapeutic strategies that protect the structure and 
retinal function against disease progression irrespective of causal genes or disease stages and which can be made 
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easily available for many patients would be highly attractive. Several clinical trials have been performed to protect 
photoreceptors via neurotrophic factors and stem cells9, yet no established therapies are available.
Valosin-containing protein (AAA-ATPase p97, VCP) is an abundant ATPase in virtually all cells, including 
neural cells of the retina. It has been reported to be essential for a number of cellular processes such as endoplas-
mic reticulum-associated degradation, DNA damage response, and cell cycle control10. Moreover, mutated VCPs 
with apparently elevated ATPase activities have been identified in two types of human genetic disorders with 
neurodegenerative phenotypes11–13.
We previously developed novel chemical modulators of VCP ATPase activity, which were selected from about 
200 newly synthesized chemical compounds based on their ability to inhibit the ATPase activity of VCP, and 
named them Kyoto University Substances (KUSs)14. We reported that KUSs showed neuroprotective effects on 
rod photoreceptors in rd10 mice14, a retinal degeneration model with a missense mutation in the Pde6b gene15. 
KUSs prevent the degeneration-associated decrease in ATP levels, endoplasmic reticulum stress (ER stress), 
and subsequent cell death of rod photoreceptors14,16, which are responsible for detection of dim light. On the 
other hand, cone photoreceptors are important for precise resolution and color vision. For clinical application of 
KUSs to patients with RP, protective effects on cone photoreceptors, long-term protective effects, and efficacies 
in later disease stages should be thoroughly proven. Thus, extended experiments with different animal models 
are warranted.
rd12 mice have a nonsense mutation in the Rpe65 gene17 and have been used as a model for retinal degener-
ation. In 1-month-old rd12 mice (at an early stage), though visual functions in the dark are severely impaired, 
visual functions in the light are relatively preserved and retinal morphologies including photoreceptor thickness 
are also relatively intact. Visual functions in the light rapidly deteriorate up to 3 months of age and then slowly 
deteriorate. The deterioration of visual function and photoreceptor integrity are slowly progressive even after the 
age of 13 months (later disease stages)18.
Mouse eyes are different from human eyes in that mice lack the macula where cone density is highest in 
humans. Rabbits are known to have a visual streak, where the rod and cone photoreceptor density is highest, 
about 3 mm ventral to the optic nerve head (ONH)19. Recently, a transgenic rabbit with a rhodopsin Pro 347 Leu 
mutation, which is found in RP patients, has been developed as a mid-sized model for RP (RP rabbits)20,21. In the 
current study, we investigated whether KUS121 (Fig. 1a)14,16, one of the KUSs, has neuroprotective effects on cone 
photoreceptors in rd12 mice, both in earlier disease stages and in later disease stages when retinal degeneration 
has progressed. Importantly, we expanded our study to confirm the neuroprotective effects of KUS121 in RP 
rabbits.
Results
KUS121 attenuates visual function loss in rd12 mice. Firstly, in order to investigate whether KUS121 
affects the electroretinogram (ERG), 3-month-old wild-type mice were assessed by photopic and scotopic ERG 
before and after daily administration of KUS121 (ad libitum access to water containing KUS121 for 7 days). 
The amplitudes of the b-wave, which was derived from bipolar cells22, and the a-wave amplitude, which has 
been reported to reflect rod function23, did not significantly differ before and after the KUS121 administration 
(Fig. 1b).
We then investigated the efficacy of KUS121 on rd12, a mouse model for retinal degeneration. After the age 
of 1 month, KUS121 or water as a control were daily administered orally to rd12 mice (Supplementary Fig. S1a). 
Nine months after the start of medication (at 10 months of age), the protective effect of KUS121 on photore-
ceptors was functionally assessed by ERG. In scotopic ERG, a-wave was already undetectable at the age in both 
control and KUS-treated groups18. However, photopic ERG was measurable, which allowed us to evaluate cone 
functions in rd12 mice. The b-wave amplitude was significantly larger in rd12 mice administered KUS121 than 
in control mice at 10 months (Fig. 1c,d; 8.7 ± 4.3 μ V, 6.6 ± 2.6 μ V, respectively, at stimulus intensity of 10 cds/m2. 
Mean ± SD. P = 0.02, unpaired t test.).
KUS121 has protective effects on cones even in the later disease stage of rd12 mice. We next 
examined potential efficacies of KUS121 on photoreceptors in the later stage of disease; daily oral administra-
tion of KUS121 was started with 13-month-old rd12 mice, when retinal degeneration had already progressed 
(Supplementary Fig. S1b). At this age, among the two groups, the total retinal thickness and the photoreceptor 
thickness measured on spectral-domain optical coherence tomography (SD-OCT) images were not signifi-
cantly different (Fig. 2a,b; P = 0.43 and P = 0.07, respectively, unpaired t test). Six months after the start of treat-
ment (19 months of age), the layers became thin in the control rd12 mice. By contrast, the extent of thinning in 
KUS121-treated rd12 mice was less severe. Total retinal and photoreceptor layers were significantly thicker in rd12 
mice treated with KUS121 than non-treated controls (total retinal thickness: 195.9 ± 8.2 and 184.9 ± 10.2 μ m, 
respectively, P < 0.001; photoreceptor layer thickness: 45.8 ± 6.9 and 39.4 ± 7.4 μ m, respectively, P < 0.01, 
unpaired t test; Fig. 2a–c).
Hematoxylin and eosin (HE)-stained 19-month-old rd12 retinal sections showed more nuclei of photoreceptors 
in the outer nuclear layer (ONL) in KUS121-treated mice (KUS121 treatment for 6 months) than in controls, 
indicating significant efficacy of KUS121 on photoreceptor survival (Fig. 2d). These observations were further con-
firmed by experiments with quantitative reverse transcription polymerase chain reaction (qRT-PCR) of rhodopsin 
mRNA in the retinas; the levels of retinal rhodopsin mRNA from 19-month-old rd12 mice administered KUS121 
was significantly higher than controls without KUS121 administration (P = 0.047; Supplementary Fig. S2).
Immunohistochemical analyses showed staining of middle wavelength-sensitive opsin (M-opsin), which is 
a photopigment of cones that is sensitive to light in the middle of the visible spectrum, is more intense in rd12 
treated with KUS121 than controls (Fig. 2e). Staining with Peanut Agglutinin (PNA), which has been used to label 
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cones24, also revealed that the numbers of cones retained in rd12 mice treated with KUS121 were greater than 
those in control rd12 mice without KUS121 treatments (Fig. 2f).
At the age of 19 months, b-wave amplitudes of photopic ERGs were significantly larger in rd12 mice that were 
administered KUS121 for 6 months than controls (16.3 ± 8.1 and 12.2 ± 5.0 μ V, respectively, P = 0.017, at stimulus 
intensity of 10.0 cds/m2, and 22.5 ± 14.1 and 16.3 ± 8.2 μ V, respectively, P = 0.030, at stimulus intensity of 30.0 cds/m2; 
Fig. 3a,b).
These results suggest that KUS121 protects photoreceptors, including cone photoreceptors, both morpholog-
ically and functionally, in a mouse model for retinal degeneration.
KUS121 delays retinal degeneration in a rabbit model for retinal degeneration. Next, we veri-
fied the efficacies of KUS121 on a mid-sized model for RP. Rabbits are known to have a visual streak, where the 
rod and cone photoreceptor density is highest19. We used transgenic rabbits with mutated rhodopsin (Pro 347 
Leu, RP rabbits) as a model for RP20. KUS121 (50 mg/kg/day) was daily administered to RP rabbits after the age 
of 3 weeks (Supplementary Fig. S1c). At 10 weeks of age, thickness of the ONL in KUS121-treated RP rabbits 
(KUS121 treatment for 7 weeks) near the ONH was larger than that in control RP rabbits (P = 0.030, Tukey test; 
Fig. 4a). Mean b-wave amplitude of the scotopic 0.01 ERG (at stimulus intensity of 0.01 cds/m2), which associates 
with rod response, was larger in the KUS121-treated RP rabbits (KUS121 treatment for 9 weeks) than in con-
trol RP rabbits at the age of 12 weeks (121.1 ± 14.6 and 87.3 ± 24.1 μ V, respectively, P = 0.0012, unpaired t test; 
Fig. 4b). The mean a-wave amplitude of scotopic 3.0 or 30 ERG (at stimulus intensity of 3.0 or 30 cds/m2), which 
originates from both rods and cones, was also larger in the KUS121-treated RP rabbits than in control RP rabbits 
(49.2 ± 7.4 and 36.6 ± 10.1 μ V, respectively, at the intensity of 3.0 cds/m2, P = 0.0038, unpaired t test; Fig. 4c,d). 
Figure 4e shows representative HE-stained retinal sections of 20-week-RP rabbits (KUS121 treatment for 17 
weeks). As observed in rd12 mice, there were more nuclei of photoreceptors in the ONL in KUS121-treated RP 
Figure 1. Effects of KUS121 on visual function in rd12 mice in light-adapted conditions. (a) Chemical 
structure of KUS 121, one of the VCP (valosin-containing protein) modulators14. (b) Influence of KUS121 
itself on electroretinography (ERG) was evaluated in wild-type (WT) mice (12 eyes of 6 mice) before and after 
daily KUS 121 administration for 7 days. b-wave amplitudes of light-adapted ERG at stimulus intensity of 10 or 
30 cds/m2. The black bars show the average amplitudes. N.S.: no significant differences. (c,d) Visual function was 
evaluated by ERG in 10-month-old rd12 mice administered KUS121 for 9 months, or vehicle/water as a control 
(26 eyes of 13 mice each). (c) b-wave amplitudes of light-adapted ERG at stimulus intensity of 10 or 30 cds/m2. 
* P < 0.05 (Unpaired t test). The black bars show the average amplitudes. (d) Individual light-adapted ERGs at 
stimulus intensity of 30 cds/m2 from 10-month-old rd12 mice that exhibited the median b-wave amplitudes.
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Figure 2. Effects of KUS121 on retinal structure at a later disease stage. (a–c) Spectral-domain optical 
coherent tomography (SD-OCT) examinations were performed at the start of administration (13 months old) 
and 6 months after the start of KUS121 or water (as a control) administration in rd12 mice (31 eyes of 16 mice 
and 33 eyes of 17 mice, respectively, at 13 months, and 23 eyes of 13 mice and 22 eyes of 13 mice, respectively, at 
19 months). (a,b) Total retinal thickness (a) and the photoreceptor layer thickness ((b) the sum of outer nuclear 
layer thickness and photoreceptor inner/outer segment layer thickness, black bars in (c)) measured by SD-OCT. 
* * P < 0.01, * * * P < 0.001 (Unpaired t test). (c) Representative SD-OCT images of 19-month-old rd12 mice 
retinas administered KUS121, or water as a control. (d) Hematoxylin and eosin (HE) stained retinal sections 
of 19-month-old rd12 mice. (e,f) Retinal sections of 19-month-old rd12 mice administered KUS121, or water 
as a control, were stained with an anti-M-opsin antibody (red, e), or with cone-specific (PNA) lectin (green, 
f). Nuclei were counter-stained with DAPI (blue). RNFL: Retinal nerve fiber layer; GCL: Ganglion cell layer; 
IPL: Inner plexiform layer; INL: Inner nuclear layer; OPL: Outer plexiform layer; ONL: Outer nuclear layer; 
IS: Inner segment of the photoreceptor cell; OS: outer segment of the photoreceptor cell; RPE: Retinal pigment 
epithelium. Error bars indicate standard deviation in (a,b). Scale bars: 50 μ m in (d), 20 μ m in (e,f).
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rabbits than controls. These results show that KUS121 has a significant protective effect on photoreceptors, both 
morphologically and functionally, in this rabbit model of RP.
KUS121 prevents ER stress, activates mTOR, and suppresses apoptosis in the eyes of RP animal 
models. In order to elucidate the mechanisms of retinal protection by KUS121, expression levels of 
stress-related proteins were analyzed using extracts of both neural retina and a mixture of RPE, choroid, and 
sclera (RPE/choroid) from 19-month-old rd12 mice. Expression of C/EBP-homologous protein (CHOP), 
which is upregulated in response to ER stress25, was reduced both in neural retina and RPE/choroid of 
KUS121-administered rd12 mice (KUS121 treatment for 6 months) (Fig. 5a).
Reduction of ER stress in the eyes of KUS121-treated rd12 mice was supported by immunohistochemical 
analysis. In the eyes of 19-month-old control rd12 mice, CHOP expression was detected in the ONL, the inner 
nuclear layer (INL), and also choroid (red signals in Fig. 5b). In contrast, only weak expression of CHOP was 
detected in the eyes of KUS121-treated mice (KUS121 treatment for 6 months) (Fig. 5b). In the rabbit model, high 
expression of CHOP was detected in the outer segment (OS) of photoreceptors in 10-week-old control RP rabbits 
(green signals in Fig. 5c). Compared to these non-treated RP rabbits, the expression of CHOP was suppressed in 
RP rabbits treated with KUS121 (KUS121 treatment for 7 weeks) (Fig. 5c). VCP expression was not affected by 
KUS121 treatment (Fig. 5a).
Mammalian target of rapamycin (mTOR) is a regulator of cell growth, proliferation, and survival26,27, and 
is activated after phosphorylation of Ser2481 and Ser244826,28. The ratio of phosphorylated-mTOR (pmTOR) 
to actin in the RPE/choroid was less in control rd12 mice than in the age-matched wild-type (WT) mice 
(Supplementary Fig. S3a,b). The ratio was larger in the eyes of rd12 mice with KUS121 than without KUS121 
(Supplementary Fig. S3b). These data show that activation of mTOR was suppressed in the rd12 mice, and 
mTOR activation was partially restored with KUS121 treatment, albeit the level was still lower than in WT mice 
(Supplementary Fig. S3a,b).
To ascertain whether suppression of ER stress and activation of mTOR with KUS121 treatment may prevent 
apoptosis, we examined cleaved caspase-3, which is generated in apoptotic cells. Western blot analysis revealed 
that the amount of cleaved caspase-3 was less in the retinas of rd12 mice administered KUS121 than in retinas 
without KUS121 (Supplementary Fig. S3c). That is, apoptosis inducer caspase-3 was less activated in retinas of 
KUS121-treated mice.
These experiments confirmed that KUS121 suppressed ER stress and partially restored mTOR activation, 
followed by suppression of apoptosis.
Discussion
In the current study, we found that one of the VCP modulators, KUS121, suppressed apoptosis and worked 
against photoreceptor cell death in animal models of RP. KUS121 protected photoreceptors, including cone 
photoreceptors, both morphologically and functionally, in rd12 mice and RP rabbits. KUS121 protected pho-
toreceptors by reducing ER stress and partially restored mTOR activation, followed by suppression of apoptosis. 
Moreover, the protective effects of KUS121 in rd12 mice were confirmed even when the medication was started 
Figure 3. Effects of KUS121 on visual function at a later disease stage. Visual function in 19-month-old 
rd12 mice administered KUS121 for 6 months up until the examination, or water as a control, was measured by 
ERG (24 eyes of 15 mice and 26 eyes of 15 mice, respectively). (a) b-wave amplitudes of light adapted ERG at 
stimulus intensity of 10 or 30 cds/m2. The black bars indicate the average amplitudes. * P < 0.05 (Unpaired t test). 
(b) Light-adapted ERGs at a stimulus intensity of 30 cds/m2 from 19-month-old rd12 mice that exhibited the 
median b-wave amplitudes for the control and KUS121 groups, respectively.
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Figure 4. Neuroprotective effects of KUS121 in a rabbit model of retinal degeneration. (a) Comparison 
of the outer nuclear layer (ONL) thickness in 10-week-old P347L rhodopsin transgenic rabbits (RP rabbits) 
administered KUS121 for 7 weeks (n = 8 eyes), or vehicle (5% Cremophor/PBS) as a control (n = 14 eyes), and 
wild-type (WT) rabbits (n = 6 eyes). ONL thickness was measured on images produced by SD-OCT. The x-axis 
represents the distance from the lower edge of the optic nerve head (ONH). * P < 0.05, KUS121 vs. control,  
* * * P < 0.001, control and KUS121, vs. WT, Tukey test. (b,c) b-wave amplitudes of dark-adapted ERG at a 
stimulus intensity of 0.01 cds/m2 (b) and a-wave amplitudes of dark-adapted ERG at a stimulus intensity of 
3.0 cds/m2 (c) in 12-week-old RP rabbits administered KUS121 for 9 weeks (n = 8 eyes ) or vehicle (control, 
n = 12 eyes). * * P < 0.01 (Unpaired t test). (d) Dark-adapted ERGs at a stimulus intensity of 30 cds/m2 from 
12-week-old rabbits that produced the median b-wave amplitudes. (e) HE-stained retinal sections of eyes from 
20-week-old rabbits administered KUS121 for 17 weeks or vehicle (control). RNFL: Retinal nerve fiber layer; 
GCL: Ganglion cell layer; IPL: Inner plexiform layer; INL: Inner nuclear layer; ONL: Outer nuclear layer; IS: 
Inner segment of the photoreceptor cell, and OS: outer segment of the photoreceptor cell. Error bars indicate 
standard deviation in (a–c). Scale bar: 50 μ m in (e).
www.nature.com/scientificreports/
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at 13 months of age, when the degeneration had progressed considerably, which approximates the situation in 
patients with advanced symptoms.
In retinitis pigmentosa, ER stress has been reported to be involved in disease progression29,30. Indeed, expres-
sion of CHOP, an ER stress marker, was upregulated in rd12 mice and RP rabbits. KUS121 reduces ER stress in 
the retina of these animals (Fig. 5). On the other hand, mTOR is a regulator of cell growth, proliferation, and 
survival26,27 and impairment of mTOR signaling is related to apoptosis27,31. mTOR is activated after phosphoryl-
ation of Ser2481 and Ser244826,28 and mTOR signaling is stimulated by amino acids, hormones, and mitogens, 
while it is impaired in response to cellular stresses, including DNA damage, nutrient withdrawal, and depletion 
of cellular energy, and hypoxia31,32. We confirmed that activation of mTOR was suppressed in rd12 mice as previ-
ously reported33. In contrast, KUS121 treatment partially restored mTOR activation (Supplementary Fig. S3). In 
our previous study, we reported that KUSs suppressed the ATPase activity of VCP, an abundant ATPase in cells, 
and consequently suppressed the decrease of ATP levels without affecting the other known cellular activities of 
VCP14,16. Since mTOR can be suppressed by cellular ATP shortage31, it is a likely possibility that KUS121 partially 
restored mTOR activity by maintaining ATP levels rather than activating mTOR directly. This possibility remains 
to be clarified.
In conclusion, we showed that KUS121 protected not only rod but also cone photoreceptors, which are impor-
tant in central vision and in quality of vision. In typical RP patients, central vision is retained until the later stages 
of the disease. The protection of these remaining cone photoreceptors is clinically very important to preserve the 
central vision in RP patients. The fact that KUS121 had significant protective effects on cone photoreceptors even 
in the later stages of the animal models leads us to expect that neuroprotection, as shown by KUS121, can be a 
very promising strategy toward the treatment of RP patients.
Methods
Experimental Animals. This study was conducted in accordance with the Association for Research in 
Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. All 
Figure 5. Suppression of CHOP by KUS121. (a) Neural retinas (retina) and a mixture of retinal pigment 
epithelium (RPE), choroid, and sclera (RPE/choroid) from 19-month-old rd12 mice were separately collected 
and analyzed by western blotting using anti-C/EBP-homologous protein (CHOP) and anti-VCP antibodies. 
Actin was used as a loading control. Complete scans of western blots are shown in Supplementary Fig. S4.  
(b,c) Retinal sections of 19-month-old rd12 mice (6-month treatment) (b) or 10-week-old RP rabbits (7-month 
treatment) (c) with or without KUS121, were stained with anti-CHOP antibody (red in (b) and green in (c)). 
Nuclei in (c) were counter-stained with DAPI (blue). INL: Inner nuclear layer; ONL: Outer nuclear layer; IS: 
Inner segment of the photoreceptor cell, and OS: outer segment of the photoreceptor cell. C: control; K121: 
KUS121. Scale bars: 20 μ m in (b,c).
www.nature.com/scientificreports/
8Scientific RepoRts | 6:31184 | DOI: 10.1038/srep31184
protocols were approved by the Institutional Review Board of Kyoto University Graduate School of Medicine 
(MedKyo 10157, 10158, 11228, 11229, 12245, 12246, 13221, 13222, 14213, 15531). rd12 mice17 were obtained 
from the Jackson Laboratory (Bar Harbor, ME, USA). Wild-type mice (C57/BL6) were purchased from Japan 
SLC, Inc. Mice were maintained in a 14 hour light/10 hour dark cycle and were fed ad libitum. New Zealand 
White rabbits (NZW, WT) and rabbits with a rhodopsin P347L mutation (NZW, RP rabbits)20 were purchased 
from Kitayama Labes Co., Ltd (Ina, Nagano, Japan). All rabbits were kept under a 14 h–10 h light-dark cycle 
(approximately 200 lux), given free access to water, and fed once a day. Before image or ERG acquisition, mice 
and rabbits were anesthetized with an intramuscular injection of a mixture of ketamine (70 mg/kg) and xylazine 
(14 mg/kg) (mice) or ketamine (25 mg/kg) and xylazine (2 mg/kg) (rabbits). Pupils were dilated with tropicamide 
and phenylephrine eye drops (0.5% each).
Administration of KUS121. We measured the amount of water that mice drank with ad libitum access in 
pilot experiments and prepared KUS121 solution (water containing 384.5 mg/L of KUS121) aiming for admin-
istration of 50 mg/kg/day of KUS121, which was the amount that showed neuroprotective effects in previous 
studies14,16. One-month-old rd12 mice were assigned to either the KUS121 group (13 mice) or the control 
group (13 mice), and the KUS121 group mice were subjected to oral administration of KUS121. These mice had 
ad libitum access to water containing KUS121. In addition to this ad libitum access, between 1 month to 5 
months these mice were given oral KUS121 (50 mg/kg/day), or vehicle (5% Cremophor EL (Sigma) in phosphate 
buffered saline (PBS)) as a control, using a feeding tube in order to ensure at least 50 mg/kg/day of administra-
tion. Thirteen-month-old rd12 mice were assigned to either the KUS121 group (16 mice) or the control group 
(17 mice) and given oral KUS121 (384.5 mg/L KUS121 in drinking water) or water ad libitum. The decrement 
of the water containing KUS121 in the water bottles was measured, and mice were weighed to calculate the 
administration dosage with ad libitum access, with an assumption that the mice drank the entire amount of the 
decrement, while in reality some of the water is spilt in the cage. Thus, the actual administration was less than 
70 mg/kg/day with ad libitum access and was between 50 mg/kg/day to 120 mg/kg/day with ad libitum access 
combined with oral administration with feeding tubes. Three-week-old RP rabbits were assigned to either the 
KUS121 group (8 rabbits, 50 mg/kg/day) or vehicle (5% Cremophor/PBS, control) group (11 rabbits) and oral 
administration involved a feeding tube. The administration and experimental schedule for each experiment is 
shown in Supplementary Fig. S1.
SD-OCT acquisition. Fundus images were obtained using speckle noise-reduced SD-OCT with the 
eye-tracking function based on Spectralis® HRA + OCT (Multiline OCT; Heidelberg Engineering, Heidelberg, 
Germany)34. A 25-diopter adaptor lens was placed on the objective lens of the Multiline OCT to focus onto 
the mouse retina. In mice, a vertical B-scan through the ONH was obtained, along with 19 vertical B-scans 
evenly spaced over a 30° × 15° area through the optic nerve head for volume mapping. One hundred individual 
B-scans (manufacturer-set maximum) were averaged to obtain the final vertical B-scan, and 50 individual B-scans 
were averaged for each of the 19 vertical B-scans used in volume mapping around the ONH. In rabbits, vertical 
SD-OCT images, which passed through the center of the ONH and included the visual streak, were obtained by 
averaging 100 B-scans21. SD-OCT imaging was performed at 13 and 19 months (before and 6 months after the 
start of treatmemt, respectively) in rd12 mice and at 10 weeks (7 weeks after the start of treatment) in RP rabbits.
Analyses of SD-OCT images. We assessed total retinal thickness, evaluated as the distance between the 
inner limiting membrane and the outer side of the Bruch’s membrane. Photoreceptor layer thickness was evalu-
ated as the sum of ONL thickness and photoreceptor inner/outer segment layer thickness (black bars in Fig. 2c). 
The vitreoretinal interface, outer plexiform layer (OPL)/ONL, RPE anterior border, and Bruch’s membrane pos-
terior border were manually determined. The built-in software of the Spectralis HRA-OCT was then used to 
measure thickness of each layer. In mice, a volume map around the optic nerve head was used to assess total 
retinal thickness within 366 μ m of the ONH in all directions (circular area). The circular area within 122 μ m of 
the ONH was excluded from analyses. Measured values of the upper, lower, right, and left regions were averaged. 
Photoreceptor layer thickness was measured 244 μ m above and below the center of the ONH using a single verti-
cal scan. These two measurements were then averaged to obtain the final photoreceptor layer thickness measure-
ment. In rabbits, ONL thickness within the areas (0.5 mm each) 4 mm ventral to the lower edge of the ONH was 
measured by using the software supplied by Heidelberg Engineering.
ERG recording and analysis. ERG was recorded using a gold-loop corneal electrode with a light-emitting 
diode (Mayo Corp., Inazawa, Japan). A reference electrode was placed in the mouth, and a ground electrode 
was placed in the anus (in mice) or attached to the ear (in rabbits). Stimuli were produced with a light-emitting 
diode stimulator (Mayo Corp.). The ERG response signals were amplified (PowerLab 2/25; AD instruments, 
New South Wales, Australia). In photopic ERG on mice, stimulus intensity was 10.0 and 30.0 cds/m2 and a 
background illumination of 30 cd/m2 35. Thirty to 50 responses were averaged to obtain the final photopic ERG 
waveform. For scotopic ERG, rabbits were dark-adapted for more than 60 min. Stimulus intensity was 0.01 (rod 
response), 3.0 (mixed cone and rod response) and 30.0 cds/m2 35. In order to investigate whether KUS121 affected 
the ERG signal, 3-month-old wild-type mice were assessed by ERG before and after daily oral administration of 
KUS121(ad libitum access to water containing 384.5 mg/L of KUS121 for 7 days). In the RP animal models, ERGs 
were recorded at 10 months (9 months after the start of treatmnet) and 19 months (6 months after the start of 
treatment) in rd12 mice and at 12 weeks (9 weeks after the start of treatment) in RP rabbits. The a- and b-wave 
amplitudes were analyzed using Chart & Scope software (AD instruments, New South Wales, Australia).
Western blotting. Two eyes of two 19-month-old rd12 mice with KUS121 (KUS121 treatment for 6 months) 
and two eyes of two mice without KUS121 were analyzed. Immediately after enucleation, eyeballs were immersed 
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in cold Hanks’ balanced salt solution. Incisions were made through pinholes in the corneas, then using the inci-
sions the sclera was peeled to collect the mixture of the RPE, choroid and sclera separately from the neural retina. 
The lens and iris were removed. The neural retina was analyzed separately from the mixture of RPE, choroid, and 
sclera (RPE/choroid).
Histological Evaluation of Retinas. Eyeballs of 19-month-old rd12 mice and 20-week-old rabbits were 
enucleated after pentobarbital overdose. A suture was placed on the edge of the superior conjunctiva to identify 
the superior portion of the retina. The eyes were fixed in 4% paraformaldehyde for 24 hours (in mice) or a glut-
araldehyde and formaline mixture for 24 hours and 10% formaline for another 24 hours (in rabbits) at 4 °C, then 
embedded in paraffin. Serial 6-μ m paraffin-embedded sections were cut through the suture and at the point of 
insertion of the optic nerve. Sections that included the center of the optic nerve head were stained with HE or 
with antibodies and photographed under an optical microscope (BZ-9000, Keyence).
Antibodies and lectin. Polyclonal antibodies against VCP were developed in our laboratory as described 
previously36. Anti-CHOP antibody was purchased from Santa Cruz Biotechnology (CA, USA); anti-M-opsin and 
anti-actin antibodies were purchased from Millipore (MA, USA); anti-cleaved caspase-3, anti-phospho-mTOR 
(Ser 2481), anti-phospho-mTOR (Ser 2448), and anti-mTOR antibodies were purchased from Cell Signaling 
(MA, USA). Lectin PNA was purchased from Molecular Probes (MA, USA).
qRT-PCR. The levels of rhodopsin mRNA were analyzed by qRT-PCR: forward primer, 5′ -TTGGG 
CCCACAGGCTGTAA-3′ ; and reverse primer, 5′ -CCGAAGCGGAAGTTGCTCA-3′ . Actin was used as the 
internal standard. The mRNA was reverse transcripted and then complementary DNA was amplified by PCR 
with SYBR premix Ex Taq polymerase (Takara Bio Inc., Shiga, Japan) and 60 °C as annealing temperature using 
7300 Real-Time PCR System (Applied Biosystems, CA, USA). The neural retina was harvested as described in 
the Western blotting section above. Four eyes from 4 rd12 mice aged 19 months administered KUS121 (KUS121 
treatment for 6 months) and 6 eyes from 6 rd12 mice aged 19 months without KUS121 were separately analyzed.
Statistical Analysis. Data are presented as mean ± standard deviation (SD). Unpaired t tests were used to 
compare parameters of mice and rabbits with or without KUS121. Paired t tests were used to compare parameters 
of wild-type mice before and after KUS121 administration. ONL thicknesses in rabbits (Fig. 4a) were analyzed by 
analysis of variance (ANOVA) with repeated measurements and Tukey HSD post-hoc test. The level of statistical 
significance was set at P < 0.05.
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